BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stasi C, Silvestri C, Voller F. Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res. 2020;9:1-7. [PMID: 32095435 DOI: 10.7774/cevr.2020.9.1.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kumar M, Pahuja S, Khare P, Kumar A. Current Challenges and Future Perspectives of Diagnosis of Hepatitis B Virus. Diagnostics 2023;13:368. [DOI: 10.3390/diagnostics13030368] [Reference Citation Analysis]
2 Gildiz S, Minko T. Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer. Pharm Res 2022. [DOI: 10.1007/s11095-022-03434-4] [Reference Citation Analysis]
3 Chen S, Liu X, Liu H, Lou J. The incidence rate, serological characteristics and cytokines profile of occult HBV infection in clinic.. [DOI: 10.21203/rs.3.rs-2171086/v1] [Reference Citation Analysis]
4 Park CO, Kim HL, Park JW. Microneedle Transdermal Drug Delivery Systems for Allergen-Specific Immunotherapy, Skin Disease Treatment, and Vaccine Development. Yonsei Med J 2022;63:881-91. [PMID: 36168240 DOI: 10.3349/ymj.2022.0092] [Reference Citation Analysis]
5 de Wit JBF, Adam PCG, den Daas C, Jonas K. Sexually transmitted infection prevention behaviours: health impact, prevalence, correlates, and interventions. Psychology & Health 2022. [DOI: 10.1080/08870446.2022.2090560] [Reference Citation Analysis]
6 Murdaca G, Noberasco G, Olobardi D, Lunardi C, Maule M, Delfino L, Triggiani M, Cardamone C, Benfaremo D, Moroncini G, Vacca A, Susca N, Gangemi S, Quattrocchi P, Sticchi L, Icardi G, Orsi A. Current Take on Systemic Sclerosis Patients' Vaccination Recommendations. Vaccines (Basel) 2021;9:1426. [PMID: 34960174 DOI: 10.3390/vaccines9121426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Ayithan N, Tang L, Tan SK, Chen D, Wallin JJ, Fletcher SP, Kottilil S, Poonia B. Follicular Helper T (TFH) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients. Front Immunol 2021;12:735913. [PMID: 34512670 DOI: 10.3389/fimmu.2021.735913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
9 Tsounis EP, Tourkochristou E, Mouzaki A, Triantos C. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol 2021;27:2727-57. [PMID: 34135551 DOI: 10.3748/wjg.v27.i21.2727] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]